DOI:
10.1055/s-00000142
Frauenheilkunde up2date
LinksClose Window
References
Zdenkowski N, Forbes JF, Boyle FM. et al.
Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial.
Ann Oncol/ESMO 2016;
27: 806-812
We do not assume any responsibility for the contents of the web pages of other providers.